Literature DB >> 34091113

Specific sweat metabolite profile in ocular Behcet's disease.

Xiaoxiao Cui1, Liming Zhang1, Guannan Su1, Aize Kijlstra2, Peizeng Yang3.   

Abstract

BACKGROUND: Behcet's disease (BD) is an autoimmune disorder with the serious possibility of blindness, calling for further research on its pathogenesis. Our aim was to study the metabolite composition of sweat in BD and to identify possible biomarkers.
METHODS: Metabolomics analysis was performed on sweat samples from 20 BD patients and 18 normal controls by liquid chromatography tandem mass spectrometry.
RESULTS: A significantly different metabolic profile of sweat was observed when BD patients were compared with healthy controls. The result of the orthogonal partial least squared-discrimination analysis (OPLS-DA) showed that these two comparison groups could be separated with a relatively satisfactory fitting degree (R2Y = 0.995 and Q2 = 0.817 in positive ion mode; R2Y = 0.991 and Q2 = 0.721 in negative ion mode). Based on OPLS-DA, a panel of metabolites was selected as candidate biomarkers, including l-citrulline, l-pyroglutamic acid, urocanic acid, 2-oxoadipic acid, cholesterol 3-sulfate, and pentadecanoic acid.
CONCLUSION: This is the first report on the metabolite profile of sweat in BD. Our results demonstrated a significantly different metabolite composition of sweat in BD compared to that of healthy controls.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Behcet’s disease; Biomarker; Metabolomics; Sweat

Mesh:

Substances:

Year:  2021        PMID: 34091113     DOI: 10.1016/j.intimp.2021.107812

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  1 in total

1.  Probabilistic quotient's work and pharmacokinetics' contribution: countering size effect in metabolic time series measurements.

Authors:  Mathias Gotsmy; Julia Brunmair; Christoph Büschl; Christopher Gerner; Jürgen Zanghellini
Journal:  BMC Bioinformatics       Date:  2022-09-16       Impact factor: 3.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.